Collegium Pharmaceutical (COLL) Current Deferred Revenue (2014 - 2026)

Collegium Pharmaceutical has reported Current Deferred Revenue for 10 years, with the latest figure at $667000.0 in Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 99.61% year-over-year to $667000.0 in Q2 2026; TTM through Jun 2026 was $667000.0, a 99.61% decrease from a year earlier, with the FY2025 full-year figure at $667000.0, changed N/A from the prior year.
• Current Deferred Revenue was $667000.0 for Q2 2026 at Collegium Pharmaceutical, roughly flat from $667000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $197.8 million in Q3 2024, with the low at $667000.0 in Q3 2025.
• Average Current Deferred Revenue over 5 years is $110.7 million, with a median of $152.5 million recorded in 2023.
• The largest YoY upside for Current Deferred Revenue was 36.21% in 2025 against a maximum downside of 99.66% in 2025.
• Over 5 years, Current Deferred Revenue stood at $156.9 million in 2022, then decreased by 4.53% to $149.8 million in 2023, then soared by 32.05% to $197.8 million in 2024, then plunged by 99.66% to $667000.0 in 2025, then changed by 0.0% to $667000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $667000.0 (Q2 2026), $667000.0 (Q1 2026), and $667000.0 (Q4 2025), per Business Quant data.